Focused On-demand Library for Phosphoribosyltransferase domain-containing protein 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9NRG1

UPID:

PRDC1_HUMAN

Alternative names:

Alternative UPACC:

Q9NRG1; B7Z1Z3; Q53HA7; Q59EL9; Q5VV18; Q5VV20

Background:

Phosphoribosyltransferase domain-containing protein 1, identified by the accession number Q9NRG1, exhibits minimal phosphoribosyltransferase activity in vitro. It has the capability to bind molecules such as GMP, IMP, and alpha-D-5-phosphoribosyl 1-pyrophosphate (PRPP), indicating a specific, albeit limited, role in cellular processes. Despite its low activity, the protein's interaction with these molecules suggests a nuanced function within the cell, potentially related to purine metabolism or GMP salvage pathways.

Therapeutic significance:

Understanding the role of Phosphoribosyltransferase domain-containing protein 1 could open doors to potential therapeutic strategies. Its unique interactions and activity profile make it a candidate for further investigation in the context of drug discovery, aiming to elucidate its potential impact on disease mechanisms and treatment options.